TMB-301: Ibalizumab Plus OBR Demonstrates Virologic Efficacy, Safety in Patients With Multidrug-Resistant HIV at Week 24
Conference Capsule - Novel monoclonal antibody appears less effective in patients with low baseline CD4+ cell counts. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - February 19, 2017 Category: Infectious Diseases Source Type: research
LATTE: Sustained Virologic Suppression With Oral Cabotegravir Plus Rilpivirine in Treatment-Naive Patients Through Week 144
Conference Capsule - Ad hoc analysis suggests continued use of cabotegravir plus rilpivirine. following induction-maintenance treatment safe and effective. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - February 19, 2017 Category: Infectious Diseases Source Type: research
GS-US-236-0128 OLE: Switch From Boosted PI to EVG/COBI/FTC/TAF Effective and Well Tolerated in HIV-Infected Women at Week 48
Conference Capsule - Open-label extension phase of women-only WAVES study observed improvement in bone and renal markers with switch to EVG/COBI/FTC/TAF. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - February 19, 2017 Category: Infectious Diseases Source Type: research
First Report of Possible Emergence of Integrase Resistance in Treatment-Naive Patient Receiving Dolutegravir Plus NRTIs
Conference Capsule - Patient with an acute OI experienced virologic failure on dolutegravir-based therapy followed by subsequent resuppression with ART intensification. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - February 17, 2017 Category: Infectious Diseases Source Type: research
GEHEP-002: Occurrence of HCC After SVR in HIV/HCV-Coinfected Patients Increased in IFN-Free DAA Era
Conference Capsule - No evidence of increased HCC incidence linked to DAA use in this observational Spanish cohort; results may reflect uptick in use of HCV therapy in advanced liver disease. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - February 17, 2017 Category: Infectious Diseases Source Type: research
DOLUMONO: Switch from Suppressive Combination ART to Dolutegravir Monotherapy Associated with Increased Virologic Failure and Emergent INSTI Resistance at Week 48
Conference Capsule - Extended follow-up reverses noninferiority previously observed at Week 24. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - February 17, 2017 Category: Infectious Diseases Source Type: research
DRIVE: Novel NNRTI Doravirine Plus NRTIs Noninferior to Darunavir/Ritonavir Plus NRTIs in Treatment-Naive Patients at Week 48
Conference Capsule - Doravirine was well tolerated with very low incidence of resistance. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - February 17, 2017 Category: Infectious Diseases Source Type: research
SWORD-1 and -2: Switch to Dolutegravir Plus Rilpivirine Noninferior to Remaining on Baseline ART at Week 48 in Virologically Suppressed Patients
Conference Capsule - Two-drug regimen maintained virologic suppression in 95% of patients over 48 weeks and improved bone turnover markers despite increase in low-grade, drug-related adverse events following switch. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - February 17, 2017 Category: Infectious Diseases Source Type: research
Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients
Learning Module - Jos é R. Arribas, MD, discusses the rationale for and clinical trial data on the modification of virologically suppressive antiretroviral therapy regimens, including important considerations for individualized decision making. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - January 31, 2017 Category: Infectious Diseases Source Type: research
Contemporary Management of HIV: New Data From IAC 2016
Slideset - In this downloadable slideset, Daniel R. Kuritzkes, MD, and Program Director Eric S. Daar, MD, review key new HIV data presented at the AIDS 2016 meeting. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - January 20, 2017 Category: Infectious Diseases Source Type: research
Contemporary Management of HIV: New Data From CROI 2016
Slideset - In this downloadable slideset, Joseph J. Eron, Jr., MD, and Program Director Eric S. Daar, MD, review key new HIV data presented at the Boston 2016 meeting. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - January 20, 2017 Category: Infectious Diseases Source Type: research
Contemporary Management of HIV: When to Start, What to Start
Slideset - In this downloadable slideset, Daniel R. Kuritzkes, MD, and Program Director Eric S. Daar, MD review key data and optimal approaches for first-line ART with contemporary HIV regimens. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - January 20, 2017 Category: Infectious Diseases Source Type: research
Contemporary Management of HIV: Managing ART in HIV-Infected Patients With Common Comorbidities
Slideset - In this downloadable slideset, David A. Wohl, MD, and Program Director Eric S. Daar, MD, review key data and optimal approaches for managing ART in the context of common comorbidities. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - January 20, 2017 Category: Infectious Diseases Source Type: research
Contemporary Management of HIV: Managing HIV in Viral Hepatitis Coinfection
Slideset - In this downloadable slideset, David L. Wyles, MD, and Program Director Eric S. Daar, MD, review key data and optimal approaches for ART management in patients with HIV and viral hepatitis coinfection. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - January 20, 2017 Category: Infectious Diseases Source Type: research
Contemporary Management of HIV: Modifying Antiretroviral Therapy in Virologically Suppressed Patients and Those With Treatment Failure
Slideset - In this downloadable slideset, W. David Hardy, MD, and Program Director Eric S. Daar, MD review key data and optimal approaches for modifying ART in patients who are virologically suppressed or have experienced treatment failure. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - January 20, 2017 Category: Infectious Diseases Source Type: research
